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Summary 
Background Many evidence-based preventive services are unaffordable. Pay-it-forward offers 
an individual a gift (e.g. a test for sexually transmitted diseases) and then asks whether they 
would like to give a gift (e.g. a future test) to another person. This study examined the 
effectiveness of a pay-it-forward program to increase gonorrhea and chlamydia testing among 
men who have sex with men (MSM) in China. 
Methods We conducted a randomized controlled superiority trial at three HIV testing sites run 
by MSM community-based organizations between November 2018 to January 2019. We 
included MSM aged 16 and older seeking HIV testing who met indications for gonorrhea and 
chlamydia testing. Restricted randomization was employed using computer-generated permuted 
blocks. Thirty groups were 1:1:1 randomized into three arms: a pay-it-forward arm where men 
were offered free gonorrhea and chlamydia testing and then asked whether they would like to 
donate others’ tests; a pay-what-you-want arm where men were offered free testing and given the 
option to pay any desired amount for the test; and a standard-of-care arm where testing was 
offered at 150RMB (US$22). There was no masking to arm assignment. The primary outcome 
was gonorrhea and chlamydia test uptake ascertained by administrative records. We used 
generalized estimating equations to estimate intervention effect with one-sided 95% confidence 
intervals and a pre-specified superiority margin, 20%. The trial was registered (NCT03741725). 
Findings Three hundred and one men were recruited and included in the analysis: 101 were 




uptake in the pay-it-forward, pay-what-you-want, and standard of care arms were 56% (57/101), 
46% (46/100), and 18% (18/100), respectively. The estimated difference in test uptake between 
pay-it-forward and standard-of-care was 38.4% (95% CI lower bound: 28.4%). Among men in 
the pay-it-forward arm, nearly all (54/57, 94.6%) chose to donate to support testing for others. 
Interpretation Pay-it-forward strategy can increase gonorrhea and chlamydia testing among 
Chinese MSM and may be a useful tool for scaling up preventive services that carry a mandatory 
fee. 
Funding NIH, TDR, the National Key Research and Development Program of China, Doris 






Many evidence-based preventive services are not affordable for individuals in resource-limited 
settings.(1, 2) Despite recommendations from the World Health Organization and others to make 
healthcare universally accessible,(3) individuals routinely pay out-of-pocket fees for vaccines, 
drugs, and diagnostics.(4) Mandatory fees decrease health service utilization and reduce 
equitable access by disproportionately affecting the poor.(5-7) Public sector programs that 
subsidize preventive services are under increasing financial strain(8) and altering prices is 
difficult.(9) Programs to reduce fees associated with preventive services have not been scaled 
up.(4, 10) Innovative strategies are needed to expand access to preventive services.  
 
One novel strategy for promoting service uptake in health is the pay-it-forward health services 
provision model.(11) With pay-it-forward, one person receives a gift and then is asked whether 
he or she would like to give a similar gift to another person.(12) A single-city observational 
study used pay-it-forward to have men who have sex with men (MSM) receive a free 
gonorrhea/chlamydia test. Then each participant decides whether to donate toward the next 
person’s test. One observational study found that a pay-it-forward approach substantially 
increased gonorrhea and chlamydia testing among MSM.(11) Pay-it-forward changes the 
conventional transactional exchange between buyer and seller to a social exchange between gift 
receivers and givers.(13) This approach may increase trust and community engagement in health 
services which have been associated with sexually transmitted infection (STI) test uptake.(14) 
 
Dual gonorrhea and chlamydia tests are available in many Chinese hospitals for approximately 




infections being highly prevalent (12.5% and 18.1% respectively, including urethral, rectal, and 
pharyngeal sites), often asymptomatic, and associated with increased risk of HIV transmission 
and acquisition.(16-18) Pay-it-forward may reduce financial barriers to testing while engaging 
local MSM communities.  
 
The purpose of this multi-site, three-arm, randomized controlled trial (RCT) is to evaluate the 
effectiveness of a pay-it-forward model for increasing dual gonorrhea and chlamydia test uptake 
among Chinese MSM compared to a standard fee-based system. The primary outcome is uptake 
of dual gonorrhea and chlamydia testing. The secondary objective of this study is to evaluate the 
cost-effectiveness of the interventions in comparison to the standard of care. 
 
Methods 
Study setting and design 
We conducted this multi-site RCT between November 2018 to January 2019 in two Chinese 
cities: Guangzhou (two sites in hospital-based STI clinics), and Beijing (in a community-based 
organization). All sites offered free HIV testing and were run by MSM community-based 
organizations (Guangzhou: Zhitong Guangzhou LGBT Center; Beijing: Blued) as a common 
service delivery mode in China.(19) HIV testing was performed using a third generation HIV 
rapid test (InTec, Xiamen, China). We chose those sites because they already provided HIV 
testing services, included laypersons (no physicians), and were affiliated with a local 
community-based organization, which is common for HIV testing service delivery in China for 
key populations. This provides a strong foundation for pay-it-forward and makes our research 




protocol.(20) The study was approved by ethics review committees at Southern Medical 
University Dermatology Hospital (China), University of North Carolina at Chapel Hill (USA), 
and Yale University (USA). This trial was registered on ClinicalTrials.gov (NCT03741725). We 
reported our findings according to the Consolidated Standards of Reporting Trials (CONSORT) 
cluster-extension guidelines.(21)  
 
We employed a group-based RCT design based on the following reasons: First, the intervention 
was framed as a group-based intervention in terms of donations from more than one MSM 
supported testing costs. Second, research studies in China suggest that peer influences on HIV 
test uptake are important (22, 23) and that men who are accompanied for STI/HIV testing are 
significantly more likely to receive testing when accompanied by a partner(24). Our study design 
assigned partners within the same group, appreciating these social influences. Finally, our study 
was designed as a pragmatic trial in order to be relevant to other community-based sites that 
deliver HIV testing services. After discussions with our community partners, there was 
agreement that an individual-based RCT would interfere with normal clinical service provision 
and not be feasible in a real-world setting. 
 
Participants 
We recruited participants from men seeking HIV testing at the study sites. Participants were 
eligible if they were born biologically male, aged 16 years or older, ever had anal sex with a 
man, had not tested for gonorrhea and chlamydia in the past 12 months, and were willing to 
provide a cell phone number or WeChat ID for results notification. All participants provided 





Randomization and masking 
Groups of ten men were randomly assigned (1:1:1) to one of the three study arms: pay-it-
forward, pay-what-you-want, or standard of care. A group was defined as a group of ten eligible 
men that arrived in order at the study site and agreed to participate. We chose a group size of ten 
based on sample size calculation and implementation consideration (Supplementary File 5). All 
men in the same group were assigned to the same study arm. Men who presented with partners 
were assigned to the same group as their partners.  
 
We generated the randomization sequence using STATA 15 software prior to recruitment 
(Supplementary File 6).(25) Three groups, one from each arm, were bundled as a triplet and 
permutated within triplets to ensure balanced arms (1:1:1) at each site. After randomization, sites 
with a high volume of men visiting to test for HIV received more triplets, such that the study 
period remained relatively the same across sites. Study organizers and participants were not 
masked to arm assignment.  
 
Procedures 
The pay-it-forward program was developed using crowdsourcing to solicit community input.(11) 
Crowdsourcing has a group solve a problem and then share solutions with the community.(26) 
First, program procedures were designed through an iterative consultation process with 
community partners and were piloted at each of the three study sites. The pilot included a total of 
43 men and based on its results, community partners and study staff optimized the standard 
operating procedure.(20) Second, the name of the program in Chinese was crowdsourced from 




earlier participants were presented to subsequent participants in the pay-it-forward arm. Figure 1 
shows the key concepts of the pay-it-forward and pay-what-you-want models applied in 
gonorrhea and chlamydia testing. 
 
Men in all three study arms were introduced to gonorrhea and chlamydia testing and the study 
procedures of their respective arm. Men in pay-it-forward were told that the standard price of the 
gonorrhea and chlamydia testing was 150RMB ($22US), and that previous participants who 
cared about them donated toward testing fees. Thus, men in the pay-it-forward arm received a 
free test, and then decided whether, and if so, how much to donate toward future testing for 
others. Participants were shown postcards and told that testing and donating were voluntary. 
 
After being introduced to the testing and the study, men in the pay-what-you-want arm were told 
that the standard price of gonorrhea and chlamydia testing was 150 RMB ($22US), and that they 
would receive free testing and then decide the amount that they would like to pay for their own 
test. 
 
Men in the standard of care arm received the same introduction to gonorrhea and chlamydia 
testing as the men in the other two arms. They were then told that the standard price of gonorrhea 
and chlamydia testing was 150 RMB (US$22) and they had to pay the full amount for their 
testing. 
 
In all three arms, men who decided to test were asked about their sexual practices and advised to 




sample were immediately collected after they made the decision to test. All men were invited to 
complete a survey about their sexual history, testing history, and attitudes toward the testing 
program, and towards the MSM community at each site (Supplement File 1). Samples at all sites 
were transported to Southern Medical University Dermatology Hospital laboratory in Guangzhou 
for nucleic acid amplification testing (NAAT). We chose NAAT because of the superior 
sensitivity, higher specificity, and Chinese regulatory approval. Patients who tested positive were 
counseled and directed to the web page of the designated partner hospital in each city, where 
they would be able to make an appointment to receive treatment and follow-up. Details on 
procedures for sample processing, payment method, and laboratory testing can be found 
elsewhere.(20) The trial stopped once the pre-determined sample size was reached. 
 
Outcomes 
The primary outcome was gonorrhea and chlamydia test uptake immediately after the 
intervention as assessed by administrative records. Secondary outcomes included incremental 
cost per test and incremental cost per diagnosis. We categorized costs into fixed and variable 
costs from a health-provider perspective and with a within-trial time horizon. We first calculated 
the total economic cost for each arm, then divided these costs by the number of men tested and 
by the number of new gonorrhea or chlamydia cases detected in each study arm. We also report 
for each intervention the incremental cost-effectiveness ratios (ICERs) for cost per additional 
person tested and case identified. Details of the cost and cost-effectiveness analyses are 
summarized in the Supplemental File 2. Other psychosocial outcomes investigated include 
community engagement,(14) community connectedness,(28, 29) and social cohesion,(30, 31) 






We used descriptive analyses to examine participants’ socio-demographic characteristics in each 
arm. To account for potential correlation in outcomes within groups, generalized estimating 
equations modeling (GEE) was used to assess the population-averaged effect of the pay-it-
forward and pay-what-you-want interventions on test uptake compared to standard of care. 
Correlation structure within groups was specified as equal correlation (the exchangeable option 
on STATA). Additionally, Huber/White/sandwich estimator of variance was used instead of the 
conventional variance estimator so that the model estimates were robust even if the correlation 
structure was mis-specified. A binomial distribution was specified for test uptake with the 
identity link function in order to obtain the absolute difference in the proportions of test uptake. 
Key sociodemographic variables incorporated into the model as covariates included age as a 
continuous variable and study site as a nominal variable to account for potential confounding. 
For details see Supplement File 4. A superiority margin of 0.2 (20% difference in probability of 
agreeing to test comparing interventions to standard of care) was pre-specified as a clinically 
significant difference in gonorrhea and chlamydia test uptake based on what would be clinically 
relevant and a previous modeling study(32). The sample size has sufficient power to detect this 
difference (Supplement File 5). For the test uptake proportion differences, per study design using 
superiority by a margin test, one-sided 95% confidence intervals were computed comparing pay-
it-forward and pay-what-you-want respectively to standard of care, where the lower bounds were 






Between December 2018 and January 2019, a total of 431 men were screened for study 
eligibility. Fifteen were deemed ineligible for having already participated in a pay-it-forward 
pilot study before (n=6), having tested for gonorrhea and/or chlamydia in the past 12 months 
(n=5), having never had anal sex with men (n=3), and not born biologically male (n=1). Then, 
115 eligible men declined to participate due to lack of interest or a time conflict, resulting in a 
final sample of 301 men who were enrolled and assigned to groups. Figure 2 presents the study 
flow from recruitment to outcome assessment.  
 
Table 1 presents the sociodemographic and sexual behavior characteristics of men assigned by 
arm. There was no statistically significant difference between those variables among men 
assigned to the three study arms. Overall, most men were 30 years old or younger (71.5%), never 
married (87.5%), and their highest education was a Bachelor’s or above (85.1%). Their annual 
income varied, with 11.5% in the lowest category (<2,680 USD, converted from Chinese Yuan), 
and 38.2% in the highest category (> 14,294 USD).  
 
Approximately half of men (51.1%) reported having multiple sexual partners in the past three 
months, and 234 (81.5%) men reported having anal sex in the past three months. Among these, 
more than half (54.3%) reported consistent condom use during anal sex in the past three months.  
 
Proportions of men agreeing to receive gonorrhea and chlamydia test in the pay-it-forward, pay-
what-you-what, and standard of care arms were 56%, 46%, and 18% respectively (Table 2). GEE 
output suggested that the pay-it-forward arm was associated with a 38% increase in test uptake 




sided 95% confidence interval with the lower bound at 28%, greater than the 20% superiority 
margin. After adjusting for participants age and site, the finding remained unchanged 
(probability difference: 0.39, one-sided 95% CI lower bound: 0.28).  
 
Compared to standard of care, the pay-what-you-what intervention was associated with a 28% 
absolute increase in the proportion of men receiving a gonorrhea and chlamydia test, with a 
lower bound, one-sided 95% CI of 16%, less than the 20% superiority margin but still greater 
than 0. After adjusting for participant age and site, this finding also remained unchanged (risk 
difference: 0.28, one-sided 95% CI lower bound: 0.15). As with the pay-it-forward arm, age and 
testing site location were not significantly associated with the primary outcome. Alternative 
multivariable models adjusting for additional covariates were tested and yielded similar results 
(Supplement File 4). 
 
Among 121 participants who tested for gonorrhea and chlamydia (40.2%, 121/300), five (4.1%) 
men had gonorrhea infection and 19 (15.7%) men had chlamydia infection. Among all 301 men, 
seven (2.3%) had a positive test for HIV infection. 
 
A complete cost and cost-effectiveness analysis is provided in Supplement File 2. In summary, 
the total health provider economic cost (including start-up, test kits, staff time, overheads) for 
pay-it-forward ($1125) and for pay-what-you-want ($967) were higher than that of the standard 
of care ($612). Of the 57 men who received testing through the pay-it-forward arm, 54 (94.6%) 
chose to donate some amount toward testing of future participants. Among the 46 men who 




ICER using economic costs per additional person tested was $12.68 (pay-what-you-want 
compared with standard of care) and $14.27 (pay-it-forward compared with pay-what-you-want). 
The ICER using financial costs per additional person tested was: $12.96 (pay-it-forward 
compared with standard of care) and pay-it-forward dominated (i.e. cheaper and more effective 
than) pay-what-you-want. Key study procedures and findings were summarized in a video 
(Supplement File 3). 
 
Discussion 
The goal of this study was to assess the superiority of a pay-it-forward strategy to standard of 
care in promoting STI testing among MSM in China. We found that a pay-it-forward strategy 
increased STI testing and generated a substantial portion of costs associated with testing. This 
extends the literature by using an RCT and suggests that pay-it-forward strategies may increase 
uptake of screening services that would otherwise be associated with fees.  
 
We found that men in the pay-it-forward arm had higher gonorrhea and chlamydia test uptake. 
This finding is consistent with one observational study(11) and some literature supporting pay-it-
forward outside of health.(12, 13, 33) This effect of pay-it-forward may be related to free testing 
and/or the specific context in which men knew that other men from their community cared about 
them. The high rates of test uptake in the pay-what-you-want arm suggests that free testing itself 
may be responsible for a substantial portion of the test uptake effect. However, the specific 






We found that nearly all men offered pay-it-forward voluntarily chose to donate to testing for 
future men. The total donation amount was $473 and the average donation amount was $8.29. 
This pay-it-forward donation covered 42% (473/1125) of the total economic cost for 
implementing pay-it-forward. The high donation rate and associated cost reduction suggest that 
pay-it-forward may help extend existing preventive services. This is particularly relevant to 
China and other low- and middle- income countries, where few resources have been allocated to 
non-HIV STI prevention and related services.(15, 18) Donations from a pay-it-forward program 
could allow more individuals to receive free or subsidized STI testing services. Pay-it-forward 
could be relevant in other settings in which groups of individuals pay mandatory fees for 
preventive services. 
 
Our study has several limitations. This study was conducted in two metropolitan cities in China 
and making inferences to other settings should be done with caution. At the same time, there are 
many low- and middle- income settings in which well-defined populations pay fees for 
preventive health services. Several aspects of the trial were designed to enhance generalizability 
to other community-based HIV testing sites: no doctors were involved in implementation; 
protocols were streamlined into routine services; and messaging was simplified. Future studies 
should investigate the transferability of using pay-it-forward to promote preventive service 
uptake in other resource-constrained settings. Although there are other examples of MSM 
community financing for health services (34), the potential for this approach to be integrated into 
existing health systems has not been explored. Second, we evaluated this approach in a research 
context. We did not examine whether pay-it-forward might work in practice, although an earlier 




effectiveness analysis used a short-term time horizon and did not calculate the disability-adjusted 
life years averted or quality adjusted life years gained. Therefore, our results are a conservative 
estimate of the likely benefit from the interventions, as earlier diagnosis and treatment of STIs 
could also reduce onward transmission of the STI to other sexual partners and reduce the 
morbidity from the STI. There is currently no consensus on the willingness to pay per additional 
person tested for chlamydia or gonorrhea, or for an additional person diagnosed with chlamydia 
or gonorrhea. However, one study of cost-utility of screening for chlamydia and gonorrhea 
among MSM reported potential cost-effectiveness for screening.(35) 
 
This study has implications for research and policy. From a research perspective, this expands 
the limited trial data examining the effectiveness of interventions related to behavioral 
economics and social innovation. Further RCTs and qualitative research studies will be 
important to understand the pay-it-forward mechanism of action and scalability. Our study may 
have generated a “warm glow”, a rewarding positive feeling from doing one’s part to help 
others,(36) that seemed to inspire both participants and research staff, but this was not captured 
in our pre-specified outcomes. In this study, men could donate money for subsequent testers or 
write a simple postcard for other community members. Given that MSM are marginalized in 
China and many other LMIC settings, programs spurring social engagement, such as pay-it-
forward, could potentially build collective agency and social cohesion. From a policy 
perspective, this intervention is not meant to replace public provision of STI testing services for 
subpopulations. However, this type of program may be useful as a temporary measure to 
generate testing demand and build trust in new services, prior to the introduction of more 





In conclusion, pay-it-forward can increase gonorrhea and chlamydia testing among Chinese 
MSM. Our study offers an innovative solution to supplementing testing services through 
leveraging the power of the local community. Pay-it-forward may be a useful tool for the scale-
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Research in context 
Evidence before this study 
Gonorrhea and chlamydia are common sexually transmitted infections among men who have sex 
with men in many low and middle-income countries. However, there are few interventions 
focused on increasing gonorrhea and chlamydia test uptake. We performed a PubMed and 
Google Scholar search for studies reporting gonorrhea and chlamydia testing in Chinese MSM 
with the terms “MSM”, “China”, “testing” or “screening” or “intervention.” There were no data 
restrictions and the search was performed on 19 November 2019. We identified three studies 
showing that gonorrhea and chlamydia testing uptake are low among MSM in China. We found 
one observational study evaluating the impact of a pay-it-forward approach to increase gonorrhea 
and chlamydia testing. We did not find any randomized controlled trials or costing studies 
evaluating a pay-it-forward approach.  
Added value of this study 
This study examined a pay-it-forward model for gonorrhea and chlamydia testing among 
Chinese MSM. We found that a pay-it-forward model increased test uptake compared to the 
standard of care. The program generated donations from local MSM and was cost-effective. This 
study expands the literature by formally evaluating pay-it-forward using a randomized controlled 
trial.  
Implications of all available evidence 
Our research study found that pay-it-forward increased gonorrhea and chlamydia test uptake. 
The high rates of donating suggest substantial generosity, independent of income level. This 
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Figure 1. Concepts of standard of care, pay-it-forward, and pay-what-you-want gonorrhea/chlamydia testing. 
This schematic illustrates respective trial arms from the perspective of a participant. In standard of care, participant 
was offered a test at standard price ($22 USD). In pay-it-forward, the participant was offered a gift of a free test 
(“test kit”), and told that previous men donated to make this test possible as well as shown postcards written by 
previous men (“caring”). Then, the participant was asked whether they would donate toward testing for future men 
(“voluntary donation”). In pay-what-you-want, the participant was offered a free test (“test kit”). Then, the 























Figure 2. Study flow chart, 2018-2019.  
Note: There is no loss-to-follow-up in this study. Participants made decisions on whether or not to test immediately 
after being assigned to their study arms.   
  
Assessed for eligibility (n=431) 
Excluded (n=130) 
• Not born biologically male: 1 
• No previous anal sex with man: 3 
• Participated in pay-it-forward: 6 
• Tested for gonorrhea and chlamydia 
in past 12 months: 5 
• Not interested and others: 115 




























Table 1. Sociodemographic and behavioral characteristics of MSM in three RCT arms, 2018-2019 (N= 288‡). 
 








Age (years)     
<=30 206/288 (71.5) 66/98 (67.4) 74/93 (79.6) 66/97 (68.0) 
>30 82/288 (28.5) 32/98 (32.7) 19/93 (20.4) 31/97 (32.0) 
Mean ±SD 28.1±7.1 28.6±7.8 26.6±5.6 29.1±7.5 
Marital status     
Never married 252/288 (87.5) 87/98 (88.8) 84/93 (90.3) 81/97 (83.5) 
Other** 36/288 (12.5) 11/98 (11.2) 9/93 (9.7) 16/97 (16.5) 
Highest Education     
Middle school or below 16/288 (5.6) 5/98 (5.1) 5/93 (5.4) 6/97 (6.2) 
High/vocational school 27/288 (9.4) 8/98 (8.2) 9/93 (9.7) 10/97 (10.3) 
College or above 246/288 (85.1) 85/98 (86.7) 79/93 (84.9) 81/97 (83.5) 
Annual income (USD)     
< 2,680 33/288 (11.5) 11/98 (11.2) 13/93 (14.0) 9/97 (9.3) 
2,681-5,360 26/288 (9.0) 7/98 (7.1) 9/93 (9.7) 10/97 (10.3) 
5,361-8,934 43/288 (14.9) 17/98 (17.4) 15/93 (16.1) 11/97 (11.3) 
8,935-14,294 76/288 (26.4) 23/98 (23.5) 23/93 (24.7) 30/97 (30.9) 
>14,294 110/288 (38.2) 40/98 (40.8) 33/93 (35.5) 37/97 (38.1) 
Number of sex partners in 
the past 3 months 
    
0-1 136/278 (48.9) 47/96 (49.0)  47/91(51.6) 42/91 (46.2) 
Multiple 142/278 (51.1) 49/96 (51.0) 44/91 (48.4) 49/91 (53.8) 
Had anal sex in the past 3 
months 
    
Yes 234/287 (81.5) 84/98 (85.7) 73/93 (78.5) 77/96 (80.2) 
No  53/287 (18.5) 14/98 (14.3) 20/93 (21.5) 19/96 (19.8) 
Condom use frequency 
during anal sex in past 3 
months† 
    
Non-use 14/234 (6.0) 5/84 (6.0) 5/73 (6.9) 4/77 (5.2) 
Sometimes 24/234 (10.3) 6/84 (7.1) 9/73 (12.3) 9/77 (11.7) 
Often 69/234 (29.5) 21/84 (25.0) 24/73 (32.9) 24/77 (31.2) 
Always 127/234 (54.3) 52/84 (61.9) 35/73 (47.9) 40/77 (51.9) 
HIV testing frequency in 
past 2 years 
    
Never tested 









Once a year 63/287 (22.0) 23/98 (23.5) 16/93 (17.2) 24/96 (25.0) 
Every six months 76/287 (26.5) 26/98 (26.5) 24/93 (25.8) 26/96 (27.1) 
Every three months 73/287 (25.4) 21/98 (21.4) 25/93 (26.9) 27/96 (28.1) 











*PIF=pay-it-forward, PWYW=pay-what-you-want, SOC=standard of care 
** Includes engaged, married, divorced or separated. 
† Question asked only to participants who reported having had anal sex in the past three months. 






Table 2. Arm participation and dual test uptake (primary outcome analysis), 2018-2019 (N=301). 
 
 



















10 <0.001 0.280 0.163  0.278  0.153 
Standard of care 
18/100 
(18%) 
10 0.028 0.000 -- 0.000 -- 
*95%CI: the lower bound one-sided 95% confidence interval 
** Prob diff: The probability difference between intervention arms (pay-it-forward or pay-what-you-want) to 
standard of care.  
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Supplement File 1. Survey instrument 
 
A. Sociodemographics 
The next set of questions will ask you to provide some information about yourself. 
 
A1. Age: ____ years old 
A2. Nationality 
1. Han Chinese 2. Other _________ 
A3. Current marital status:  
1. Never married  
2. Engaged or Married 
3. Separated or divorced     
4. Widowed 
A4. Highest level of completed education:  
1. Elementary  
2. Middle school 
3. High school or vocational school 
4. Bachelor or associate degree 
5. Above bachelor’s degree 
A5. What is your occupation? 
o Student 
o Civil servant 
o Farmer 
o Labor worker (blue collar) 
o Office worker (white collar) 
o Seller/service staff 
o Technician  
o Unemployed  
o Other______ 
 
A6. What is your total individual monthly income from all sources? 
1. <1500 RMB/month  
2. 1500-3000 RMB/month 
3. 3001-5000 RMB/month   
4. 5001-8000 RMB/month  
5. >8000 RMB/month 
  












B. Sexual behaviors 
The next set of questions will ask you about your sexual behaviors with other men. 
 
B1. What is your role during anal sex? 
1. Mostly receptive (bottom) 
2. Mostly insertive (top) 
3. Half and half (versatile) 
 






B3. In the past 3 months, have you had anal sex? 
1. Yes  
2. No (Skip to B5) 
 
B4. In the past 3 months, when you had anal sex, how frequently did you use condoms? 
1. 0% condom use  
2. Less than 50% condom use  
3. More than 50% condom use 
4. 100% condom use 
 
B5. In the past 3 months, have you had condomless vaginal sex?  
1. Yes  
2. No 
 
B6. In the past 3 months, have you had condomless oral sex?  
1. Yes  
2. No 
B7. In the past, have you told anyone about your sexuality or sexual history with men?  (Select all that apply) 
1. Yes, my long-term female partner/wife 
2. Yes, my family members 
3. Yes, my friends 
4. Yes, my healthcare providers 
5. Yes, others:_________ 
6. No one 
 
C. Clinical Information 
C1. Do you have any symptoms that you are worried may be due to an STI? 
1. Yes. Symptoms: _____________ 
2. No 
 
C2. Have you ever tested for HIV in the past? 
1. Yes    
2. No (Skip to C5) 
 
C3. When was the last time you tested for HIV? (If cannot recall exactly, please estimate) 
Year:________Month:______Day:________ 
 
C4. In the last two years, how frequently did you get tested for HIV? 
1. Less than once every two years 
2. Once a year 
3. Once every six months 
4. Once every three months 
5. Monthly 
 
C5. Today, did you agree to get tested for gonorrhea and chlamydia? 
1. Yes (Go to C6) 
2. No (Go to C7) 
 
C6 (Pay-it-forward arm). If you agreed to testing for gonorrhea and chlamydia today, what is the MAIN reason? (Choose ONE) 
1. “Pay It Forward” allowed for discounted testing 
2. “Pay It Forward” allowed paying kindness forward to community members 
3. Recent symptoms 
4. Recent high-risk sexual behavior 
5. Testing site’s staff told me to get tested  
6. A friend told me to get tested 
7. Other ____________________ 
 
C6 (Pay-what-you-want arm). If you agreed to testing for gonorrhea and chlamydia today, what is the MAIN reason? (Choose 
ONE) 
1. “Pay What You Want” allowed for discounted testing 
2. Recent symptoms 




4. Testing site’s staff told me to get tested  
5. A friend told me to get tested 
Other ____________________ 
 
C6 (Standard of care arm). If you agreed to testing for gonorrhea and chlamydia today, what is the MAIN reason? (Choose 
ONE) 
1. Because the research staff introduced gonorrhea and chlamydia testing 
2. Recent symptoms 
3. Recent high-risk sexual behavior 
4. Testing site’s staff told me to get tested  
5. Other ____________________ 
 
C7. If you did NOT agree to testing for gonorrhea and chlamydia today, why NOT? (select all that apply) 
1. I don’t know anything about gonorrhea or chlamydia 
2. I don’t want to know if I have gonorrhea or chlamydia 
3. I don’t need to get tested  
4. Too much of a hassle 
5. Too expensive 
6. I am worried about confidentiality 
7. I am afraid of pain/ discomfort 
8. I don’t want to leave sample today 
9. I am embarrassed to get tested in front of my friend/partner 
10. I am afraid that my results will be positive 
11. Other ____________________ 
 
D. Community Engagement 
The next set of questions asks about your experiences with MSM-related causes, events and organizations in your community. 
 
D1. Have you ever participated in online forums or discussions on social media (ie. Weixin, Weibo, Twitter, or other on-line 

























E. Community Connectedness 
The following set of questions asks about your feelings toward the MSM. Here, “MSM community” broadly refers to the 
collective of individuals and community organizations that have an interest in MSM-related issues. 
 
E1. You feel that you are a part of the MSM community.  
o Strongly Agree 
o Agree 
o Disagree 





E2. Participating in the MSM community is a positive thing for you.  
o Strongly Agree 
o Agree 
o Disagree 
o Strongly Disagree 
 
E3. You are proud of the MSM community.  
o Strongly Agree 
o Agree 
o Disagree 
o Strongly Disagree 
 
E4. It is important for you to be an advocate for the MSM community. 
o Strongly Agree 
o Agree 
o Disagree 
o Strongly Disagree 
 
E5. If you and your peers work together, the problems in the MSM community can be solved.  
o Strongly Agree 
o Agree 
o Disagree 
o Strongly Disagree 
 
E6. You really feel that any problems faced by the MSM community are also your own problems.  
o Strongly Agree 
o Agree 
o Disagree 
o Strongly Disagree 
 
E7. The diagram below is designed to represent your relationship (“Self”) with LGBT as a group ("LGBT"). Please indicate your 






F. Social Cohesion 
F1. You can count on other MSM in your group of friends if you need to borrow money.  
o Strongly Agree 
o Agree 
o Disagree 
o Strongly Disagree 
 
F2. You can count on other MSM in your group of friends if you need to talk about your problems. 
o Strongly Agree 
o Agree 
o Disagree 
o Strongly Disagree 
 
F3. You can count on other MSM in your group of friends if you need somewhere to stay. 
o Strongly Agree 
o Agree 
o Disagree 
o Strongly Disagree 
 
F4. The group of MSM with whom you socialize with is an integrated group. 
o Strongly Agree 
o Agree 
o Disagree 
o Strongly Disagree 
 
F5. You can trust the majority of the MSM you know. 






o Strongly Disagree 
 
F6. In general, MSM in your group of friends in the area where you live only worry about themselves  
o Strongly Agree 
o Agree 
o Disagree 
o Strongly Disagree 
 
F7. In general the MSM you socialize with are always arguing amongst each other  
o Strongly Agree 
o Agree 
o Disagree 
o Strongly Disagree 
 
G. Pay-It-Forward Participation (Pay-it-forward arm only) 
G1. Today, you came to testing: 
1. By yourself (Skip to G3)   
2. Accompanied by someone else 
 
G2. How would you describe your relationship to the person accompanying you? 
1. Sex partner    
2. MSM peer   
3. Non-MSM peer   
4. Family     
5. Other, specify:____ 
 
G3. Did you choose to contribute any amount of money? 
1. Yes      
2. No  
 
G4. What determined your contribution amount? 
1. One’s own financial situation    
2. Normal price of testing    
3. Quality of testing service     
4. Estimate of how much others contributed      
5. Feel bad if not pay anything       
6. Other, specify:______ 
 
G5. What do you believe are the main benefits to participating in the PIF program? (select all that apply) 
1. I can receive discounted GC/CT test  
2. I can experience warm glow through receiving donated testing 
3. It reduces my STI risk by making my community healthier  
4. It can help more MSM get tested 
5. It allows someone to help me, and then I can help someone else 
6. Other ____________________ 
 
G. Pay-What-You-Want Participation  
(Pay-what-you-want arm only) 
G1. Today, you came to testing: 
1. By yourself (Skip to G3)   
2. Accompanied by someone else 
 
G2. How would you describe your relationship to the person accompanying you? 
1. Sex partner    
2. MSM peer   
3. Non-MSM peer   
4. Family     
5. Other:____ 
 
G3. Did you choose to contribute any amount of money? 
1. Yes   





G4. What determined your contribution amount? 
1. One’s own financial situation    
2. Normal price of testing    
3. Quality of testing service     
4. Estimate of how much others contributed      
5. Feel bad if not pay anything       
6. Other:_______ 
 
G5. What do you believe are the main benefits to participating in the PIF program? (select all that apply) 
1. I can receive discounted GC/CT test  
2. I can experience warm glow through receiving discounted testing 
3. It reduces my STI risk by making my community healthier  
4. It can help more MSM get tested 
5. It allows MSM to have more control over testing price 







Supplement File 2. Costing analysis results 
Costing analysis 
We estimated the full economic cost (i.e. includes the costs of all resources used to 
introduce the testing models) from a health provider perspective using a microcosting 
approach. We tracked the actual resource used in the trial and categorized cost items as 
either fixed or variable. For fixed costs (i.e. independent of number of tests conducted), we 
estimated the cost of start-up (training), capital (building rent), personnel support and 
office equipment. We annualized costs over an expected useful life of five years, including 
start-up costs, using a discount rate of 3%. For variable costs (i.e. dependent on the number 
of tests conducted), we estimated the cost of supplies used for chlamydia and gonorrhoea 
testing and personnel cost. All costs are reported in 2018 USD based on the exchange rates 
using OANDA currency conversions (1USD = 6.76 Yuan). We analyzed the cost in Excel 
2019 (Microsoft, USA).  
 
Cost-effectiveness analysis 
Using parameters from Table S1, which were informed by the trial, we created a decision-
tree model using TreeAge Pro 2019 (TreeAge Software Inc) to explore the cost-






Table S1, Unit costs of pay-it-forward, pay-what-you-want, and standard of care used 
in the model 
Tests performed USD 2018 Distribution 
- PIF* 57 Beta (55.3, 41.7) 
- PWYW* 46 Beta (45.2, 53.1) 
- SOC* 18 Beta (18.2, 83.0) 
Chlamydia or gonorrhoea diagnosed   
- PIF 8 Beta (7.9, 48.2) 
- PWYW 8 Beta (7.8, 37.0) 
- SOC 4 Beta (3.8, 13.2) 
Fixed cost PIF or PWYW or SOC Unit cost per person tested  
- Building rental 0.40 Gamma (36, 90) 
- Office equipment 0.08 Gamma (36, 432) 
- Start-up 1.22 Gamma (36, 30) 
- Total fixed cost 1.70  
Variable cost PIF   
- Supplies 14.49 Gamma (36,2)  
- Personnel 2.24 Gamma (36, 16) 
- Total variable cost 16.73  
Variable cost PWYW   
- Supplies 14.57 Gamma (36, 2) 
- Personnel 2.75 Gamma (36, 13) 
- Total variable cost 17.32  
Variable cost SOC   
- Supplies 17.50 Gamma (36, 2) 
- Personnel 7.03 Gamma (36, 5) 
- Total variable cost 24.53  
Donations/payment   
- PIF 8.29  
- PWYW 6.77  
- SOC 25.89  
*PIF=pay-it-forward, PWYW=pay-what-you-want, SOC=standard of care 
 
The total economic cost for the pay-it-forward ($1125) and for the pay-what-you-want ($967) 
arm was higher than that of the standard of care ($612). Of the 57 men who received testing 
through the pay-it-forward arm, 54 (94.6%) chose to donate some amount toward testing of 
future participants. Among the 46 men who tested through pay-what-you-want, 42 (91.3%) 
donated some amount toward future participants. The total donations/payment amount was 
$472.78 in the pay-it-forward arm, $311.39 in the pay-what-you-want arm, and $465.98 in the 
standard of care arm. The mean donation/payment amount was $8.29 (standard deviation, SD: 




men in the pay-what-you-want arm (median: $3.09, IQR: $6.36), and $25.89 in the standard of 
care arm (Three people in the standard of care arm tested for both urine and rectal samples, 
which increased the average price to higher than $22.) The economic cost per person tested was 
$19.72 in the pay-it-forward arm, $21.02 in the pay-what-you-want arm, and $34 in the standard 
of care arm, all compared to no testing. Accounting for the donations/payments made, the 
financial cost per person tested was: $11.43 in the pay-it-forward arm, $14.26 in the pay-what-
you-want arm and $8.11 in the standard of care arm.  
 
The economic cost per case detected was: $140.50 in the pay-it-forward arm, $120.88 in the pay-
what-you-want arm, and $153.00 in the standard of care arm. Accounting for the 
donations/payments made, the financial cost per case detected was: $81.50 in the pay-it-forward 
arm, $82.00 in the pay-what-you-want arm, and $36.50 in the standard-of-care arm. 
The ICER using economic costs per additional person tested was $14.27 (pay-it-forward 
compared with pay-what-you-want) and $12.68 (pay-what-you-want compared with standard of 
care). The ICER using economic costs per additional case detected was: $88.75 (pay-what-you-
want compared with standard of care), and pay-what-you-want dominated (i.e. was cheaper and 
more effective than) pay-it-forward. The ICER using financial costs per additional person tested 
was: $12.96 (pay-it-forward compared with standard of care), and pay-it-forward dominated pay-
what-you-want. The ICER using financial costs per additional case detected was: $126.34 (pay-











We calculated the incremental cost-effectiveness ratios for cost per test conducted and cost 
per chlamydia/gonorrhoea diagnosed. We chose a within-trial time horizon (i.e. less than 
one year). Projecting the long-term impact of chlamydia/gonorrhoea testing (i.e. 
accounting for secondary effects of infections averted) is beyond the scope of this analysis. 
Thus, we provide a conservative estimate of the value of these testing models. (Table S2)  
 
Table S2, Costs, effectiveness and cost-effectiveness of pay-it-forward, pay-what-you-









Test       
SOC* 6.12  0.18   
PWYW* 9.67 3.55 0.46 0.28 12.68 
PIF* 11.24 1.57 0.57 0.11 14.27 
Test positive      
SOC 6.12  0.04   
PWYW 9.67 3.55 0.08 0.04 88.75 
PIF 11.24 1.57 0.08 0 Dominated 





Test       
SOC 1.46  0.18   
PIF 6.52 5.05 0.57 0.39 12.96 
PWYW 6.56 0.04 0.46 -0.11 Dominated 
Test positive      
SOC 1.46  0.04   
PIF 6.52 5.05 0.08 0.04 126.34 
PWYW 6.56 0.04 0.08 0 Dominated 










Univariate sensitivity analyses are presented as tornado diagrams in Figures S2-6. For 
ICERs of cost per additional person tested, the biggest drivers of cost-effectiveness were 
the variable costs of supplies and the probability of testing when comparing PWYW/PIF 
with standard of care (Figures S2-3). When comparing PWYW with PIF, the biggest drivers 
of cost-effectiveness were variable costs of supplies (Figure S4).  
 
Figure S2 Tornado plot of the ICER of cost per additional person tested for PWYW vs. 






Figure S3 Tornado plot of the ICER of cost per additional person tested for PIF vs. 











For ICERs of cost per additional case diagnosed, the biggest drivers of cost-effectiveness 







Figure S5, Tornado plot of the ICER of cost per additional case diagnosed for PWYW 






Figure S6, Tornado plot of the ICER of cost per additional case diagnosed for PIF vs. 
standard of care  
 
 
Probabilistic sensitivity analyses with 100,000 runs were conducted and presented in 
acceptability curves. These figures show the probability of being cost-effective (y-axis) 
depending on the willingness to pay thresholds (x-axis). Figure S7 shows that the pay-it-
forward has a greater than 90% probability of being cost-effective than pay-what-you-want 
and standard of care, if the willingness to pay is greater than $50 per person tested.  
 






Figure S8 shows that the PIF or PWYW arms has a greater probability of being more cost-






Figure S8, Acceptability curve of the economic cost per case detected 
 
 
These conclusions from Figure S7 and S8, do not change if we take into account the 
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Model 1: adjusted for age and site 
Model 2: adjusted for age, site, and marital status. 
Model 3: adjusted for age, site, marital status, and income. 
Model 4: adjusted for age, site, marital status, income, and education 
Model 5: adjusted for age, site, income, education (high/vocational school versus Bachelor’s degree and above), and sex 
role (insertive, receptive, half and half) 





Supplement File 5. Sample size calculation for pay-it-forward and pay-what-you-
want interventions 
 





Sample sizes of 30 in group 1 and 30 in group 2, which were obtained by sampling 3 groups 
with 10 subjects each in group 1 and 3 groups with 10 subjects each in group 2, achieve 
84.515% power to detect a superiority margin difference between the group proportions of 
0.2000. The proportion in group 1 (the treatment group) is assumed to be 0.2600 under the null 
hypothesis and 0.5400 under the alternative hypothesis. The proportion in group 2 (the control 
group) is 0.0600. The test statistic used is the one-sided Z-Test (Unpooled). The intracluster 
correlation is 0.0100, and the significance level of the test is 0.050 
 
Numeric Results for Superiority Tests for the Difference of Two Proportions (Cluster-Randomized) 
───── 
Test Statistic: Z-Test (Unpooled) 
H0: P1 - P2 ≤ D0.   H1: P1 - P2 = D1 > D0. 
 
        Group 1   Group 2                           Intra-  
      Clusters/ Clusters/ Group 2 Group 1 Group 1   Cluster  
          Items     Items    Prop Prop|H0 Prop|H1 Diff|H0 Diff|H1 Corr.  
Power     K1/M1     K2/M2      P2    P1.0    P1.1 D0 D1 ICC
 Alpha 
0.84515 3/10 3/10 0.0600 0.2600 0.5400 0.2000 0.4800 0.0100
 0.050 
0.84588 4/10 4/10 0.0600 0.2600 0.5400 0.2000 0.4800 0.0500
 0.050 
 
Procedure Input Settings 
────────────────────────────────────────────────────── 
Design Tab 
Solve For: Sample Size (K1) 
Alternative Hypothesis: One-Sided (H1: D1 > D0) 
Test Type: Z-Test (Unpooled) 
Power: 0.80 
Alpha: 0.05 
M1 (Items per group  in study Group 1): 10 
K2 (groups in study Group 2): K1 
M2 (Items per group in study Group 2): 10 
Input Type: Differences 
D0 (Difference|H0 = P1.0 - P2): 0.2 
D1 (Difference|H1 = P1.1 - P2) 0.48 
P2 (Group 2 Proportion): 0.06 
ICC (Intracluster Correlation): 0.01 0.05 
 
Report Definitions 
H0 is an abbreviation for the null hypothesis. This is the hypothesis being evaluated by the statistical test. 
H1 is an abbreviation for the alternative hypothesis. This hypothesis gives the 'true' parameter values. 
Power is the probability of rejecting a false null hypothesis. It should be close to one. 
K1 and K2 are the number of groups in each study group. 
M1 and M2 are the average number of items (subjects) per group in each study grou[. 




P1.0 is the proportion for group 1 (treatment group) assuming the null hypothesis (H0). 
P1.1 is the proportion for group 1 (treatment group) assuming the alternative hypothesis (H1). 
D0 = P1.0 - P2 is the superiority margin. It is the difference assuming H0. 
D1 = P1.1 - P2 is the actual difference at which the power is calculated. 
ICC is the intracluster correlation. 





Pay-what-you-want Superiority by a Margin Tests for the Difference of Two Proportions 




Sample sizes of 80 in group 1 and 80 in group 2, which were obtained by sampling 8 groups 
with 10 subjects each in group 1 and 8 groups with 10 subjects each in study group 2, achieve 
80.448% power to detect a superiority margin difference between the group proportions of 
0.2000. The proportion in group 1 (the treatment group) is assumed to be 0.2600 under the null 
hypothesis and 0.4200 under the alternative hypothesis. The proportion in group 2 (the control 
group) is 0.0600. The test statistic used is the one-sided Z-Test (Unpooled). The intracluster 
correlation is 0.0100, and the significance level of the test is 0.050. 
 
Numeric Results for Superiority Tests for the Difference of Two Proportions (Cluster-Randomized) 
───── 
Test Statistic: Z-Test (Unpooled) 
H0: P1 - P2 ≤ D0.   H1: P1 - P2 = D1 > D0. 
 
        Group 1   Group 2                           Intra-  
      Clusters/ Clusters/ Group 2 Group 1 Group 1   Cluster  
          Items     Items    Prop Prop|H0 Prop|H1 Diff|H0 Diff|H1 Corr.  
Power     K1/M1     K2/M2      P2    P1.0    P1.1 D0 D1 ICC
 Alpha 
0.80448 8/10 8/10 0.0600 0.2600 0.4200 0.2000 0.3600 0.0100
 0.050 
0.81580 11/10 11/10 0.0600 0.2600 0.4200 0.2000 0.3600 0.0500
 0.050 
 
Procedure Input Settings 
────────────────────────────────────────────────────── 
Design Tab 
Solve For: Sample Size (K1) 
Alternative Hypothesis: One-Sided (H1: D1 > D0) 
Test Type: Z-Test (Unpooled) 
Power: 0.80 
Alpha: 0.05 
M1 (Items per group in study Group 1): 10 
K2 (Groups in study Group 2): K1 
M2 (Items per group in study Group 2): 10 
Input Type: Differences 
D0 (Difference|H0 = P1.0 - P2): 0.2 
D1 (Difference|H1 = P1.1 - P2) 0.36 
P2 (Group 2 Proportion): 0.06 






H0 is an abbreviation for the null hypothesis. This is the hypothesis being evaluated by the statistical test. 
H1 is an abbreviation for the alternative hypothesis. This hypothesis gives the 'true' parameter values. 
Power is the probability of rejecting a false null hypothesis. It should be close to one. 
K1 and K2 are the number of groups in study groups 1 and 2, respectively. 
M1 and M2 are the average number of items (subjects) per group in study groups 1 and 2, respectively. 
P2 is the proportion for group 2. This is the standard, reference, baseline, or control group. 
P1.0 is the proportion for group 1 (treatment group) assuming the null hypothesis (H0). 
P1.1 is the proportion for group 1 (treatment group) assuming the alternative hypothesis (H1). 
D0 = P1.0 - P2 is the superiority margin. It is the difference assuming H0. 
D1 = P1.1 - P2 is the actual difference at which the power is calculated. 
ICC is the intracluster correlation. 
Alpha is the probability of rejecting a true null hypothesis. 
 
 
Summary: Based on implementation considerations, we decided on a total of ten groups for each arm in 
testing the hypotheses that pay-it-forward/pay-what-you-want is superior to standard of care in terms of 






Supplement File 6. Randomization 
 
 STATA code used to generate the random allocation sequence of the three study groups in a triplet: 
 
** 1: PIF 
** 2: PWYW 
** 3: SOC 
 
*** block 1: ShengPi (study site 1) 
*** block 2& 3: ShiPi (study site 2) 
*** block 4 to 10: BlueD (study site 3) 
 
set obs 30 
egen id = seq(), to(3) 
egen block = seq(), block(3) 
set seed 666666 
gen random = uniform() 
sort block random 














Title and abstract 
 1a Identification as a randomised trial in the title Page 1 
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see 





2a Scientific background and explanation of rationale Page 4-5 
2b Specific objectives or hypotheses Page 5 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio Page 5-6 
3b Important changes to methods after trial commencement (such as eligibility criteria), with 
reasons 
N/A 
Participants 4a Eligibility criteria for participants Page 6 
4b Settings and locations where the data were collected Page 5 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and 
when they were actually administered 
Page 7-9 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how 
and when they were assessed 
Page 9 
6b Any changes to trial outcomes after the trial commenced, with reasons N/A 
Sample size 7a How sample size was determined Page 7 
7b When applicable, explanation of any interim analyses and stopping guidelines N/A 




8a Method used to generate the random allocation sequence Page 7 & 
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file 6 




9 Mechanism used to implement the random allocation sequence (such as sequentially 
numbered containers), describing any steps taken to conceal the sequence until 









10 Who generated the random allocation sequence, who enrolled participants, and who 
assigned participants to interventions 
Page 6-8 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care 
providers, those assessing outcomes) and how 
Page 7 
11b If relevant, description of the similarity of interventions N/A 
Statistical 
methods 
12a Statistical methods used to compare groups for primary and secondary outcomes Page 10 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses Page 10 
Results 
Participant flow 
(a diagram is 
strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended 
treatment, and were analysed for the primary outcome 
Page 11 
13b For each group, losses and exclusions after randomisation, together with reasons Page 11 & 
Figure 2 
Recruitment 14a Dates defining the periods of recruitment and follow-up Page 9 
14b Why the trial ended or was stopped Page 9 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group Page 21 
Numbers 
analysed 
16 For each group, number of participants (denominator) included in each analysis and whether 




17a For each primary and secondary outcome, results for each group, and the estimated effect 
size and its precision (such as 95% confidence interval) 
Page 11-13 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended Page 11-13 
Ancillary 
analyses 
18 Results of any other analyses performed, including subgroup analyses and adjusted 
analyses, distinguishing pre-specified from exploratory 
Page 11-13 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) N/A 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity 
of analyses 
Page 14-15 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings Page 14 





Registration 23 Registration number and name of trial registry Page 2&6 




Funding 25 Sources of funding and other support (such as supply of drugs), role of funders Page 3 
* This checklist was retrieved from  www.consort-statement.org.
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